Literature DB >> 27924419

Beneficial effect of low-level laser therapy in acute lung injury after i-I/R is dependent on the secretion of IL-10 and independent of the TLR/MyD88 signaling.

J L Carvalho1, A Britto2, A P Ligeiro de Oliveira2, H Castro-Faria-Neto3, R Albertini1, E Anatriello1, F Aimbire4,5.   

Abstract

The use of low-level laser for lung inflammation treatment has been evidenced in animal studies as well as clinical trials. The laser action mechanism seems to involve downregulation of neutrophil chemoattractants and transcription factors. Innate immune responses against microorganisms may be mediated by toll-like receptors (TLR). Intestinal ischemia and reperfusion (i-I/R) lead to bacterial product translocation, such as endotoxin, which consequently activates TLRs leading to intestinal and lung inflammation after gut trauma. Thus, the target of this study was to investigate the role of TLR activation in the laser (660 nm, 30 mW, 67.5 J/cm2, 0.375 mW/cm2, 5.4 J, 180 s, and spot size with 0.08 cm2) effect applied in contact with the skin on axillary lymph node in lung inflammation induced by i-I/R through a signaling adaptor protein known as myeloid differentiation factor 88 (MyD88). It is a quantitative, experimental, and laboratory research using the C57Bl/6 and MyD88-/- mice (n = 6 mice for experimental group). Statistical differences were evaluated by ANOVA and the Tukey-Kramer multiple comparisons test to determine differences among groups. In order to understand how the absence of MyD88 can interfere in the laser effect on lung inflammation, MyD88-/- mice were treated or not with laser and subjected to occlusion of the superior mesenteric artery (45 min) followed by intestinal reperfusion (4 h). In summary, the laser decreased the MPO activity and the lung vascular permeability, thickened the alveolar septa, reduced both the edema and the alveolar hemorrhage, as well as significantly decreased neutrophils infiltration in MyD88-deficient mice as well in wild-type mice. It noted a downregulation in chemokine IL-8 production as well as a cytokine IL-10 upregulation in these animals. The results also evidenced that in absence of IL-10, the laser effect is reversed. Based on these results, we suggest that the beneficial effect of laser in acute lung injury after i-I/R is dependent on the secretion of IL-10 and independent of the TLR/MyD88 signaling.

Entities:  

Keywords:  Intestinal ischemia–reperfusion; Laser therapy; Lung inflammation; Myeloid differentiation gene 88

Mesh:

Substances:

Year:  2016        PMID: 27924419     DOI: 10.1007/s10103-016-2115-4

Source DB:  PubMed          Journal:  Lasers Med Sci        ISSN: 0268-8921            Impact factor:   3.161


  45 in total

Review 1.  [Pathophysiology of ischaemia-reperfusion injury].

Authors:  Maja Sirotković-Skerlev; Stjepko Plestina; Ivan Bilić; Zdenko Kovac
Journal:  Lijec Vjesn       Date:  2006 Mar-Apr

Review 2.  Pathophysiology and implications for treatment of acute respiratory distress syndrome.

Authors:  M H van Soeren; W L Diehl-Jones; R J Maykut; W M Haddara
Journal:  AACN Clin Issues       Date:  2000-05

3.  Increased mortality and inflammation in tumor necrosis factor-stimulated gene-14 transgenic mice after ischemia and reperfusion injury.

Authors:  Danielle G Souza; Adriana C Soares; Vanessa Pinho; Humberto Torloni; Luiz F L Reis; Mauro M Teixeira; Adriana A M Dias; Mauro T Martins
Journal:  Am J Pathol       Date:  2002-05       Impact factor: 4.307

4.  Cutting edge: TLR4 activation mediates liver ischemia/reperfusion inflammatory response via IFN regulatory factor 3-dependent MyD88-independent pathway.

Authors:  Yuan Zhai; Xiu-da Shen; Ryan O'Connell; Feng Gao; Charles Lassman; Ronald W Busuttil; Genhong Cheng; Jerzy W Kupiec-Weglinski
Journal:  J Immunol       Date:  2004-12-15       Impact factor: 5.422

5.  Anti-inflammatory effects of low-level light emitting diode therapy on Achilles tendinitis in rats.

Authors:  Murilo Xavier; Débora Rodrigues David; Renato Aparecido de Souza; Arthur Nascimento Arrieiro; Humberto Miranda; Eduardo Tadeu Santana; José Antonio Silva; Miguel Angel Castillo Salgado; Flávio Aimbire; Regiane Albertini
Journal:  Lasers Surg Med       Date:  2010-08       Impact factor: 4.025

6.  Differential toll-like receptor activation in lung ischemia reperfusion injury.

Authors:  Patrick Phelan; Heather E Merry; Billanna Hwang; Michael S Mulligan
Journal:  J Thorac Cardiovasc Surg       Date:  2015-02-28       Impact factor: 5.209

7.  Low-level laser therapy restores the oxidative stress balance in acute lung injury induced by gut ischemia and reperfusion.

Authors:  Flávia Mafra de Lima; Regiane Albertini; Yvana Dantas; Antonio Luis Maia-Filho; Cristiano de Loura Santana; Hugo Caire Castro-Faria-Neto; Cristiane França; Antonio Balbin Villaverde; Flávio Aimbire
Journal:  Photochem Photobiol       Date:  2012-11-19       Impact factor: 3.421

8.  Altered expression of IL-10 family cytokines in monocytes from CRMO patients result in enhanced IL-1β expression and release.

Authors:  S R Hofmann; A S Kubasch; C Ioannidis; A Rösen-Wolff; H J Girschick; H Morbach; C M Hedrich
Journal:  Clin Immunol       Date:  2015-09-25       Impact factor: 3.969

9.  Suppressive effect of low-level laser therapy on tracheal hyperresponsiveness and lung inflammation in rat subjected to intestinal ischemia and reperfusion.

Authors:  Flávia Mafra de Lima; Luana Vitoretti; Fernando Coelho; Regiane Albertini; Ana Cristina Breithaupt-Faloppa; Wothan Tavares de Lima; Flávio Aimbire
Journal:  Lasers Med Sci       Date:  2012-05-05       Impact factor: 3.161

10.  Ischemia-reperfusion lung injury is attenuated in MyD88-deficient mice.

Authors:  William A Altemeier; W Conrad Liles; Ana Villagra-Garcia; Gustavo Matute-Bello; Robb W Glenny
Journal:  PLoS One       Date:  2013-10-11       Impact factor: 3.240

View more
  7 in total

1.  Reduced peripheral blood miR-140 may be a biomarker for acute lung injury by targeting Toll-like receptor 4 (TLR4).

Authors:  Xinyi Li; Jin Wang; Huisheng Wu; Peipei Guo; Chengyao Wang; Yanlin Wang; Zongze Zhang
Journal:  Exp Ther Med       Date:  2018-08-13       Impact factor: 2.447

2.  Beneficial effects of infrared light-emitting diode in corticosteroid-resistant asthma.

Authors:  Robson Alexandre Brochetti; Simone Klein; Paula Tatiane Alonso; Adriana Schapochnik; Amílcar Sabino Damazo; Michael R Hamblin; Maria Fernanda de Souza Setubal Destro; Adriana Lino-Dos-Santos-Franco
Journal:  Lasers Med Sci       Date:  2021-11-06       Impact factor: 3.161

Review 3.  Anti-tumor Activity of Toll-Like Receptor 7 Agonists.

Authors:  Huju Chi; Chunman Li; Flora Sha Zhao; Li Zhang; Tzi Bun Ng; Guangyi Jin; Ou Sha
Journal:  Front Pharmacol       Date:  2017-05-31       Impact factor: 5.810

4.  Photobiomodulation Therapy Restores IL-10 Secretion in a Murine Model of Chronic Asthma: Relevance to the Population of CD4+CD25+Foxp3+ Cells in Lung.

Authors:  Aurileia Aparecida de Brito; Tawany Gonçalves Santos; Karine Zanella Herculano; Cintia Estefano-Alves; Cristiano Rodrigo de Alvarenga Nascimento; Nicole Cristine Rigonato-Oliveira; Maria Cristina Chavantes; Flávio Aimbire; Renata Kelly da Palma; Ana Paula Ligeiro de Oliveira
Journal:  Front Immunol       Date:  2022-02-02       Impact factor: 7.561

5.  Photobiomodulation Improves Serum Cytokine Response in Mild to Moderate COVID-19: The First Randomized, Double-Blind, Placebo Controlled, Pilot Study.

Authors:  Seyed Mehran Marashian; Mohammadreza Hashemian; Mihan Pourabdollah; Mansour Nasseri; Saeed Mahmoudian; Florian Reinhart; Alireza Eslaminejad
Journal:  Front Immunol       Date:  2022-07-08       Impact factor: 8.786

Review 6.  Cellular Signal Transduction Pathways Involved in Acute Lung Injury Induced by Intestinal Ischemia-Reperfusion.

Authors:  Guangyao Li; Yingyi Zhang; Zhe Fan
Journal:  Oxid Med Cell Longev       Date:  2021-06-04       Impact factor: 6.543

Review 7.  Photobiomodulation therapy as a high potential treatment modality for COVID-19.

Authors:  Sepideh Soheilifar; Homa Fathi; Navid Naghdi
Journal:  Lasers Med Sci       Date:  2020-11-25       Impact factor: 3.161

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.